Molecular Partners AG (XSWX:MOLN) Interest Expense : CHF-0.03 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Molecular Partners AG's interest expense for the three months ended in Mar. 2024 was CHF -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-0.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Molecular Partners AG's Operating Income for the three months ended in Mar. 2024 was CHF -15.86 Mil. Molecular Partners AG's Interest Expense for the three months ended in Mar. 2024 was CHF -0.01 Mil. Molecular Partners AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Molecular Partners AG Interest Expense Historical Data

The historical data trend for Molecular Partners AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Interest Expense Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.30

-0.55

-0.61

-0.03

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Molecular Partners AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.03 Mil.

Molecular Partners AG (XSWX:MOLN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Molecular Partners AG's Interest Expense for the three months ended in Mar. 2024 was CHF-0.01 Mil. Its Operating Income for the three months ended in Mar. 2024 was CHF-15.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was CHF2.14 Mil.

Molecular Partners AG's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Molecular Partners AG did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.